Benzinga | Oct 8, 2021 06:45AM EDT

Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $290

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $395 to $290.